TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Metagenomi Stock

Metagenomi Stock

metagenomi.coHealthcareFounded: 2018

Metagenomi is a research and development biotech company focused on gene editing and gene therapy to treat human diseases and other ailments. The private company partners with scientists and field experts to develop gene editing systems that are derived from elements found in nature.

Buy or sell Metagenomi stockLearn more about Metagenomi IPO
Register for Details

For more details on financing and valuation for Metagenomi, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Metagenomi.

Register Today

Metagenomi investors also invested in these private companies

Novo Holdings
Leaps by Bayer
Moderna Therapeutics
SymBiosis LLC
Catalio Capital Management

Team

Management Team

Brian C. Thomas, PhD
Founder and Chief Executive Officer
Alan Cohen, MD
Chief Medical Officer and SVP of Monogenic Diseases
Jian Irish, PhD.
President and Chief Operating Officer
Simon Harnest, MSc
Chief Investment Officer and SVP of Strategy

Board Members

Jürgen Eckhardt, MD, MBA
Bayer
Sebastian Bernales, PhD
Hum­boldt Fund
Willard H. Dere, MD
University of Utah
Risa Stack, PhD
The Production Board
Santhosh Palani, PhD, CFA
PFM Data Sciences

Other companies like Metagenomi in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Cytonics
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Precision Neuroscience
Sector
Healthcare
 
 

News

Businesswire 01/17/2023
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
$100M Series B extension financing co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors, including Leaps by Bayer and Moderna, as well as the initial Series B leads PFM Health Sciences, Farallon Capital Management, and a leading global investment firm.

Trending Companies

Frequently Asked Questions